A questionnaire-based study on current trends and clinical decision drivers in the topical management of tinea infections: cross-sectional study
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20262323Keywords:
Superficial fungal infections, Topical antifungal, Luliconazole, Systemic antifungal, Tinea cruris, Tinea corporisAbstract
Background: Dermatophytosis is a common superficial fungal infection that has increasingly become recurrent and difficult to manage in routine clinical practice. However, multicentric real-world data on topical antifungal prescribing trends in India remain limited.
Methods: This multicentric, cross-sectional, questionnaire-based study was conducted among 373 dermatologists across India to evaluate current prescribing trends and clinical decision drivers in the topical management of tinea infections, with particular emphasis on luliconazole use. Data regarding disease burden, treatment practices, combination therapy, and perceptions toward advanced topical formulations were collected using a structured electronic questionnaire and analyzed descriptively.
Results: A substantial proportion of dermatologists reported that dermatophytosis accounted for 30% to 42% of routine outpatient consultations (42.09%). Poor hygiene (74.26%) and climatic factors (61.39%) were commonly perceived risk factors, while itching (94.10%) was the predominant symptom. Topical antifungal therapy was mainly preferred for localized lesions (58.45%). Luliconazole emerged as the preferred topical antifungal agent (22.25%), and 56.57% of dermatologists reported prescribing it in most patients. Combination therapy with systemic antifungal agents was frequently practiced (67.02%), particularly in recurrent or difficult-to-manage infections. High efficacy, better penetration, and improved spread ability were the most perceived benefits associated with technology-based topical formulations.
Conclusions: Dermatophytosis continues to represent a substantial burden in routine dermatology practice in India. The findings highlight widespread use of luliconazole-based topical therapy and frequent adoption of combination treatment approaches, emphasizing the importance of individualized and rational management strategies in contemporary dermatophytosis care.
References
Das A, Dutta B, Padovese V, Hay RJ, Khan SS. The changing face of dermatophytosis: from common skin disease to emerging resistant epidemic. Clin Exp Dermatol. 2026;51(5):805-13.
Kruithoff C, Gamal A, McCormick TS, Ghannoum MA. Dermatophyte infections worldwide: Increase in incidence and associated antifungal resistance. Life (Basel). 2024;14(1):1.
Singh P, Shenoy M, Girdhar M, Parasramani SG, Das A, Mishra PS, et al. Assessing the Impact of Dermatophytosis on Quality of Life Using the Dermatology Life Quality Index: A Real-World Cross-Sectional Study from India. Cureus. 2026;18(4):e106253.
Caplan AS, Gold JAW, Smith DJ, Ely JW. Diagnosis and Management of Tinea Infections. Am Fam Physician. 2025;112(4):382-92.
Marbaniang YV, Leto D, Almohri H, Hasan MR. Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte, Trichophyton indotineae. J Clin Microbiol. 2025;63(6):e01407-24.
Gupta AK, Wang T, Piguet V. Recalcitrant dermatophytosis: clinicomycological features and challenges in management. Expert Opin Pharmacother. 2025;26(18):1985-96.
Ohara S, Noguchi H, Matsumoto T, Hayashi D, Kashiwada-Nakamura K, Kubo M, et al. Topical Luliconazole Treatment for Hyperkeratotic Tinea Pedis. Mycopathologia. 2025;190(5):66.
Shenoy M, Poojari S, Rengasamy M, Vedmurthy M, Barua S, Dhoot D, et al. Management of Dermatophytosis: Real-World Indian Perspective. Indian Dermatol Online J. 2023;14(3):347-56.
Kaur M, Gupta A, Mahajan R, Gill M. Efficacy, Safety, and Cost Evaluation of the Topical Luliconazole Therapy versus Topical Clotrimazole Therapy in Patients with Localized Dermatophytosis in a Tertiary Care Hospital: An Observational Study. Int J Appl Basic Med Res. 2020;10(4):260-4.
Garg A, Sharma GS, Goyal AK, Ghosh G, Si SC, Rath G. Recent advances in topical carriers of anti-fungal agents. Heliyon. 2020;6(8):e04663.
Inamadar A, Rengasamy M, Charugulla SN. Treatment Approach for Superficial Dermatophytosis Infections and Factors Contributing for Noncompliance to Antifungal Therapy in India: An Epidemiological Survey. Clin Dermatol Rev. 2022;6(1):15-21.
Marbaniang YV, Leto D, Almohri H, Hasan MR. Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte, Trichophyton indotineae. J Clin Microbiol. 2025;63(6):e01407-24.
Trailokya AA. Difficult to treat superficial fungal infections: Which factors one should consider in clinical practice-An Indian perspective. IP Indian J Clin Exp Dermatol. 2023;9(4):249-51.
Pathania S, Rudramurthy SM, Narang T, Saikia UN, Dogra S. A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India. Indian J Dermatol Venereol Leprol. 2018;84(6):678-84.
Downloads
Published
How to Cite
Issue
Section
